You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

NAPRELAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Naprelan patents expire, and when can generic versions of Naprelan launch?

Naprelan is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in NAPRELAN is naproxen sodium. There are forty-two drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Naprelan

A generic version of NAPRELAN was approved as naproxen sodium by CONTRACT PHARMACAL on January 13th, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NAPRELAN?
  • What are the global sales for NAPRELAN?
  • What is Average Wholesale Price for NAPRELAN?
Drug patent expirations by year for NAPRELAN
Drug Prices for NAPRELAN

See drug prices for NAPRELAN

Drug Sales Revenue Trends for NAPRELAN

See drug sales revenues for NAPRELAN

Recent Clinical Trials for NAPRELAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwestern Medical GroupPhase 2
Apkar ApkarianPhase 4
National Institute of Dental and Craniofacial Research (NIDCR)Phase 4

See all NAPRELAN clinical trials

Pharmacology for NAPRELAN

US Patents and Regulatory Information for NAPRELAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-001 Jan 5, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-002 Jan 5, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-003 Jan 5, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NAPRELAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-001 Jan 5, 1996 ⤷  Sign Up ⤷  Sign Up
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-003 Jan 5, 1996 ⤷  Sign Up ⤷  Sign Up
Twi Pharms NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-002 Jan 5, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NAPRELAN

See the table below for patents covering NAPRELAN around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0438249 Formule de naproxen à absorption controlée pour l'administration une fois par jour. (Controlled absorption naproxen formulation for once-daily administration.) ⤷  Sign Up
Germany 69111832 ⤷  Sign Up
Denmark 0438249 ⤷  Sign Up
Australia 639519 ⤷  Sign Up
New Zealand 236762 ORAL NAPROXEN FORMULATION ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NAPRELAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 122012000052 Germany ⤷  Sign Up PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 122012000051 Germany ⤷  Sign Up PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 PA2011005,C0984957 Lithuania ⤷  Sign Up PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0984957 CR 2012 00035 Denmark ⤷  Sign Up PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900 C300481 Netherlands ⤷  Sign Up PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.